Fortress Biotech, INC

Fortress Biotech announced first quarter 2026 financial results, highlighted by FDA approval of ZYCUBO and a $205 million PRV sale, leading to significant net income.

Fortress Biotech announced its full-year 2025 financial results and corporate highlights, including FDA approvals, significant asset monetizations, and advancements in its clinical pipeline.

Fortress Biotech said majority-owned Cyprium closed the $205 million sale of its FDA Priority Review Voucher, redeemed its 9.375% preferred stock, and Fortress expects at least $100 million in aggregate proceeds subject to obligations.

Fortress Biotech's majority-owned subsidiary, Cyprium Therapeutics, entered an agreement to sell a Rare Pediatric Disease Priority Review Voucher for $205 million in cash, leading to significant loan covenant amendments.

Fortress Biotech and its subsidiary Cyprium Therapeutics announced FDA approval for ZYCUBO, the first and only treatment for Menkes disease, securing a Rare Pediatric Disease Priority Review Voucher.

Fortress Biotech amended its credit agreement, extending the loan maturity to June 2028 and issuing warrants for 600,000 common shares to lenders.

Fortress Biotech Inc. reported a significant net income of $110.4 million for Q1 2026, largely due to a $158.9 million gain from the sale of a Priority Review Voucher.

Fortress Biotech reported a significant turnaround to net income in Q3 2025, driven by strategic asset monetizations and increased product revenue from its dermatology portfolio.

Fortress Biotech reported a significant increase in net income for Q2 2025, driven by the deconsolidation gain from the sale of Checkpoint Therapeutics to Sun Pharma, despite ongoing operating losses.

Fortress Biotech's Q1 2025 results show a slight revenue increase, driven by the launch of Emrosi, alongside a pending acquisition of Checkpoint Therapeutics by Sun Pharma.

Fortress Biotech's Q3 2024 results show a net loss of $12.9 million, impacted by decreased revenue and increased interest expenses, while the company paused preferred stock dividends.

Fortress Biotech's Q2 2024 results show a decrease in revenue and a net loss, alongside strategic moves including debt restructuring and a pause in preferred stock dividends.

Fortress Biotech significantly reduced its net loss in 2025, driven by strategic asset monetizations and product approvals, despite ongoing operating losses and a paused preferred stock dividend.

Fortress Biotech's 2024 10-K filing details financial results, key developments including UNLOXCYT approval, and the pending acquisition of Checkpoint Therapeutics.

Fortress Biotech's 10-K filing provides a detailed overview of its capital stock, preferred stock, outstanding warrants, and various employee stock programs.

Fortress Biotech's Chief Financial Officer, David Jin, was granted 400,000 restricted stock units as part of his compensation.

Fortress Biotech's Chief Financial Officer, David Jin, acquired 2,967 shares of common stock at $2.176 per share through an employee stock purchase plan.

Fortress Biotech, Inc. increased its beneficial ownership in Avenue Therapeutics, Inc. by 111,209 shares of common stock as an annual dividend.

Fortress Biotech Director Dov Klein was granted 27,322 restricted shares, which were deferred into share units with a vesting schedule through 2029.

Fortress Biotech Director Jimmie Harvey was granted 27,322 restricted shares, deferred into units vesting over three years.

Fortress Biotech Director Kevin Lorenz received a grant of 27,322 restricted common shares under the company's 2013 Stock Incentive Plan.

Fortress Biotech's upcoming annual meeting will address director elections, auditor ratification, executive compensation, and a certificate of incorporation amendment.

Fortress Biotech is holding its annual stockholder meeting on June 17, 2025, to elect directors, ratify the accounting firm, approve executive compensation, and amend the corporate charter to include officer exculpation.

Fortress Biotech, Inc. will hold its annual stockholder meeting virtually on May 23, 2024, to vote on director elections, ratification of KPMG LLP, and amendments to stock incentive plans.

Fortress Biotech is holding its annual stockholder meeting to elect directors, ratify auditors, and approve amendments to its stock incentive and purchase plans.

Fortress Biotech, Inc. filed an S-1 registration statement for the resale of 600,000 common shares underlying warrants issued to Oaktree affiliates in connection with a credit agreement amendment.

Fortress Biotech is registering the resale of approximately 6.2 million shares of its common stock by existing selling stockholders, including shares issuable upon exercise of warrants.

Fortress Biotech's CEO, Lindsay A. Rosenwald, M.D., increased his beneficial ownership to 20.7% of the company's common stock following recent equity grants.

Fortress Biotech, Inc. has increased its beneficial ownership in Avenue Therapeutics, Inc. to 13.4% following an annual equity grant.

Fortress Biotech, Inc. has increased its beneficial ownership in Mustang Bio, Inc. to 8.0% following an annual equity grant and maintains a voting majority through preferred stock.

Fortress Biotech, Inc. has reported a decrease in its beneficial ownership of Mustang Bio, Inc. common stock, falling below the 5% threshold as of September 29, 2025.

Fortress Biotech, Inc. has ceased to be a beneficial owner of Checkpoint Therapeutics, Inc. common stock following the latter's merger with a subsidiary of Sun Pharmaceutical Industries, Inc.

Fortress Biotech, Inc. has filed an Amendment No. 5 to its Schedule 13D, updating its beneficial ownership in Mustang Bio, Inc. to 7.9% and reaffirming its control through Class A preferred stock.

Highbridge Capital Management, LLC has filed a Schedule 13G, reporting beneficial ownership of 7.8% of Fortress Biotech, Inc. common stock, primarily through warrants.